CXCL10 and fibrosarcoma: For example, a preclinical study found pretreatment with trabectedin improved the response to anti–PD-1 in a murine model of fibrosarcoma and led to upregulation of CD8, GZMB, PRF1, and CXCL10 mRNA expression in trabectedin-treated tumors (45).